Eg 427

eg 427 is a french biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy. by exploiting the natural properties of herpes simplex virus 1 (hsv-1), notably its ability to establish lifelong latency in peripheral neurons, eg 427 ensures highly specific and durable expression of the transgene to treat, in the long run, patients with severe, chronic and localized diseases, starting with peripheral nervous system disorders. one year after its inception, eg 427 has already built its proprietary hsv-1 vector platform and achieved the preclinical proof of its concept in the most common type of neurogenic bladder (urinary bladder dysfunction due to supra-sacral spinal cord injury). today, the company is evaluating the potential of pinpoint gene therapy in other indications that involve different compartments of the peripheral nervous system. the company expects to start its first clinical trials by 2023. based in paris, eg 427 was founded by a world-re